Jaguar Health, Inc. (JAGX) Stock Price & How to Invest

Jaguar Health, through its Napo Pharmaceuticals subsidiary, is a commercial-stage company centered on crofelemer, a plant-derived compound sourced from the Croton lechleri tree. Its approved human product, Mytesi, treats noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also has an animal-health arm, including Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and it markets Gelclair for oral mucositis. In January 2026 Jaguar out-licensed US marketing rights for Mytesi and Canalevia-CA1 to Woodward Specialty, an affiliate of privately held Future Pak, in a deal worth up to $38 million (roughly $18 million upfront plus milestones). Future Pak became the exclusive US marketer while Jaguar stays the manufacturer, giving Jaguar non-dilutive capital and letting it concentrate crofelemer development on human rare-disease indications such as intestinal failure and short bowel syndrome.

The financial reality is stark. Q1 2026 revenue was about $20.3 million, but that figure was driven almost entirely by a roughly $19 million one-time license fee; recurring prescription product revenue was only about $1.2 million. Jaguar has a long record of operating losses, going-concern uncertainty, and repeated share issuance, and its market capitalization collapsed roughly 99% during 2025 into the low single-digit millions. To hold its Nasdaq listing, it executed a 1-for-35 reverse stock split on April 30, 2026, one of several reverse splits in its history, and regained bid-price compliance on May 26, 2026. The investment picture hinges on whether the Future Pak cash and the rare-disease pipeline can stabilize a company that has repeatedly needed to raise money to keep operating.

The dominant risks are financing and dilution. Jaguar has a long history of net losses, going-concern uncertainty, and repeated share issuance and reverse stock splits, and its market cap collapsed roughly 99% during 2025 into the low single-digit millions. Recurring product revenue is very small (about $1.2 million in Q1 2026), so the headline Q1 revenue was almost entirely a one-time license fee that will not repeat each quarter. The rare-disease pipeline is early and could fail in the clinic or with regulators. The business now depends on a single external partner, Future Pak, for US commercialization of its marketed products. As a micro-cap, the stock is thinly traded and highly volatile, and further capital raises or reverse splits remain possible. This is a speculative security where a total loss is a realistic outcome.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Jaguar Health, Inc.'s investor relations page or your broker.

• Q1 2026 revenue: ~$20.3 million, but almost entirely a one-time ~$19 million license fee, not recurring sales
• Recurring product revenue (Q1 2026): ~$1.2 million for prescription products (Mytesi, Gelclair, Canalevia-CA1)
• Q1 2026 net income: ~$8.7 million, driven by the license fee rather than operations; net loss to common shareholders narrowed to ~$7.0 million
• Market capitalization: Micro-cap, roughly low single-digit millions in mid-2026 (verify live before acting)
• Share history: Multiple reverse splits, including 1-for-35 on April 30, 2026; heavy prior dilution
• Profitability track record: Long history of operating losses and going-concern uncertainty

Figures are approximate, tied to the asOf date, and distorted by one-time items and the recent reverse split, so standard valuation multiples are not very meaningful here. The Q1 2026 profit came from a one-time license fee, not sustainable operations, and per-share figures are hard to compare across reverse splits. Treat any headline number with caution and verify live data before acting; this is a speculative micro-cap where the balance sheet and financing runway matter far more than reported earnings.

There are three common ways to get JAGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so JAGX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where JAGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Jaguar Health is a micro-cap biopharma built around crofelemer (Mytesi), now leaning on a Future Pak licensing deal for non-dilutive cash while it pursues rare-disease indications. It carries serious dilution, financing, and listing risks, so it suits only speculative capital, not core holdings.